Following patient deaths in a lupus trial that led to the termination of that program, Kezar’s autoimmune candidate ...

A slow launch for Alzheimer's medicine Leqembi, a lackluster pipeline and a challenging drug launch environment are just a ...

Suggestions that the U.S. should emulate other countries on drug price controls or patents obscure how our present policies ...